Navigation Links
Phosphagenics Announces Completion of Transdermal Patch Prototypes
Date:5/29/2009

d by Phosphagenics have demonstrated that its patented technology can deliver opiates through the skin without causing any skin damage or irritation. Incorporating this technology into a patch will enable a more convenient and effective treatment that is capable of meeting the needs of pain sufferers and addresses the concerns of regulatory authorities regarding potential abuse.

In this most recent preclinical study, oxycodone concentrations produced by the patch reached approximately 160ng/ml and remained significantly elevated (p<0.01) and within therapeutic range for the duration of the four hour study. In contrast, the TPM/oxycodone gel produced peak plasma oxycodone concentrations of approximately 80ng/ml 30 minutes after application and declined from that point over the course of the trial.

"The development of our TPM patch has the potential to be a substantial commercial success for Phosphagenics," said Dr. Ogru. "Our transdermal patch should increase the amount and duration of oxycodone delivered into the systemic circulation, and could reduce potential opioid abuse, a major consideration for the FDA when reviewing possibly addictive substances such as oxycodone. In addition, our TPM skin patch should allow us to deliver other opioid based compounds, including morphine and hydromorphone, as well as other products that are targeted for delivery into the systemic circulation, including insulin. Phosphagenics has already completed a human trial that demonstrated that its TPM/insulin formulation safely delivered insulin transdermally into patients with Type 1 diabetes."

APPENDIX AND NOTES TO EDITORS

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical produc
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
3. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
4. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
5. Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
6. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
7. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
8. Medivation Announces Pricing of Public Offering
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
11. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/27/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a biopharmaceutical ... innovative therapeutics addressing cancer and other unmet medical needs ... China , today reported financial results ... 2014.  The Company reported a net ... the three months ended December 31, 2014.  This compares ...
(Date:3/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... solutions for the detection of foodborne pathogens, today ... and full year ended December 31, 2014. ... quarter ended December 31, 2014 was $1.4 million ... 2013 and $1.5 million for the third quarter ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... NEW BRUNSWICK, N.J., Dec. 5 Senesco Technologies, Inc. ... today that its Development and License Agreement with the ... mutual agreement because of Harris Moran,s recently announced corporate ... Harris Moran has reported that its parent company, Limagrain, ...
... BioCryst Pharmaceuticals (Nasdaq: BCRX ) announced today ... and BCX-4208, and clinical data on BCX-4208 at the 50th ... held in San Francisco, CA from December 6-9, 2008. ... inhibitors. , , The schedule ...
... YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, ... and commercializes differentiated products for patients worldwide, ... licensee of nimotuzumab from YM,s subsidiary, CIMYM ... the European Medicines Agency (EMEA) for marketing ...
Cached Biology Technology:Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 3YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 2YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 3
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
(Date:3/2/2015)... 2015  Businesses have a new option for ... Rankins Enterprises has announced the launch of a ... for businesses to protect their customers, personal data, ... Beconux is a biometric transaction processing system ... to an ATM machine, the new system fuses ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... of California, Berkeley, virologist and an assistant professor in the ... M. Keck Foundation grant, an award given to innovative young ... which totals up to $1 million over five years, will ... herpesvirus as a tool to study the inner workings of ...
... WORCESTER, Mass.In recent years, a class of small molecules known ... in regulating gene products in most animal and plant species. ... development of alcohol tolerance, a hallmark of alcohol abuse and ... and Alcoholism (NIAAA) report the findings in the July 31 ...
... death but now a study of brain tissue collected during ... and suicide. The international research group, led by Dr. ... of Western Ontario and Dr. Hymie Anisman of the Neuroscience ... that proteins that modify DNA directly are more highly expressed ...
Cached Biology News:UC Berkeley virologist named Keck Distinguished Young Scholar 2MicroRNA implicated as molecular factor in alcohol tolerance 2Study identifies changes to DNA in major depression and suicide 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
Biology Products: